SEC Form 4 · accession 0001439222-26-000089
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Goff
Officer — Chief Executive Officer · Director
Period of report
Jun 18, 2026
Accepted (ET)
Jun 23, 2026 · 5:17 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001439222
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance share unitsF1,F2 | — | Jun 18, 2026 | M | 39,000 | D | — | — | Common stock | 39,000 | 39,000 | D |
| Restricted stock unitsF3,F2 | — | Jun 18, 2026 | A | 39,000 | A | — | — | Common stock | 39,000 | 39,000 | D |
Explanation of responses
- F1Each performance stock unit represents a contingent right to receive one share of the issuer's common stock.
- F2Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.
- F3Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.